Search

Displaying results 4561 - 4570 of 10000 in total
  1. Drug

    Ularitide

    go.drugbank.com/drugs/DB05034
    Investigational

    Ularitide is currently in Phase 2 development as a potential treatment for patients with acute decompensated heart failure (ADHF). … When injected into the blood, ularitide appears to cause diuresis (urine output) and natriuresis (sodium excretion), as well as vasodilation.

  2. Drug

    VGV-1

    go.drugbank.com/drugs/DB05328
    Experimental

    VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

  3. Drug

    Morniflumate

    go.drugbank.com/drugs/DB09285
    Investigational

    Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid [L1496].

  4. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

  5. Drug

    Pyrrolnitrin

    go.drugbank.com/drugs/DB13603
    Experimental

    Categories: Antifungals for Topical Use, Antifungals for Dermatological Use
  6. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S. … Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in

  7. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  8. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

  9. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  10. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.